Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T76414
(Former ID: TTDC00299)
|
|||||
| Target Name |
Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
|
|||||
| Synonyms |
NR3; NR2B; NMDA receptor subunit 2B; NMDA receptor NR2B; NMDA NR2B receptor; N-methylD-aspartate receptor subtype 2B; N-methyl-D-aspartate receptor subunit 3; N-methyl D-aspartate receptor subtype 2B; HNR3; Glutamate receptor ionotropic, NMDA 2B; Glutamate receptor NR2B subunit; Glutamate [NMDA] receptor subunit epsilon-2; GluN2B
Click to Show/Hide
|
|||||
| Gene Name |
GRIN2B
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Alpha-1-antitrypsin deficiency [ICD-11: 5C5A] | |||||
| Function |
Channel activation requires binding of the neurotransmitter glutamate to the epsilon subunit, glycine binding to the zeta subunit, plus membrane depolarization to eliminate channel inhibition by Mg(2+). Sensitivity to glutamate and channel kinetics depend on the subunit composition. In concert with DAPK1 at extrasynaptic sites, acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them, resulting in an irreversible neuronal death. Contributes to neural pattern formation in the developing brain. Plays a role in long-term depression (LTD) of hippocampus membrane currents and in synaptic plasticity. Component of NMDA receptor complexes that function as heterotetrameric, ligand-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium.
Click to Show/Hide
|
|||||
| BioChemical Class |
Glutamate-gated ion channel
|
|||||
| UniProt ID | ||||||
| Sequence |
MKPRAECCSPKFWLVLAVLAVSGSRARSQKSPPSIGIAVILVGTSDEVAIKDAHEKDDFH
HLSVVPRVELVAMNETDPKSIITRICDLMSDRKIQGVVFADDTDQEAIAQILDFISAQTL TPILGIHGGSSMIMADKDESSMFFQFGPSIEQQASVMLNIMEEYDWYIFSIVTTYFPGYQ DFVNKIRSTIENSFVGWELEEVLLLDMSLDDGDSKIQNQLKKLQSPIILLYCTKEEATYI FEVANSVGLTGYGYTWIVPSLVAGDTDTVPAEFPTGLISVSYDEWDYGLPARVRDGIAII TTAASDMLSEHSFIPEPKSSCYNTHEKRIYQSNMLNRYLINVTFEGRNLSFSEDGYQMHP KLVIILLNKERKWERVGKWKDKSLQMKYYVWPRMCPETEEQEDDHLSIVTLEEAPFVIVE SVDPLSGTCMRNTVPCQKRIVTENKTDEEPGYIKKCCKGFCIDILKKISKSVKFTYDLYL VTNGKHGKKINGTWNGMIGEVVMKRAYMAVGSLTINEERSEVVDFSVPFIETGISVMVSR SNGTVSPSAFLEPFSADVWVMMFVMLLIVSAVAVFVFEYFSPVGYNRCLADGREPGGPSF TIGKAIWLLWGLVFNNSVPVQNPKGTTSKIMVSVWAFFAVIFLASYTANLAAFMIQEEYV DQVSGLSDKKFQRPNDFSPPFRFGTVPNGSTERNIRNNYAEMHAYMGKFNQRGVDDALLS LKTGKLDAFIYDAAVLNYMAGRDEGCKLVTIGSGKVFASTGYGIAIQKDSGWKRQVDLAI LQLFGDGEMEELEALWLTGICHNEKNEVMSSQLDIDNMAGVFYMLGAAMALSLITFICEH LFYWQFRHCFMGVCSGKPGMVFSISRGIYSCIHGVAIEERQSVMNSPTATMNNTHSNILR LLRTAKNMANLSGVNGSPQSALDFIRRESSVYDISEHRRSFTHSDCKSYNNPPCEENLFS DYISEVERTFGNLQLKDSNVYQDHYHHHHRPHSIGSASSIDGLYDCDNPPFTTQSRSISK KPLDIGLPSSKHSQLSDLYGKFSFKSDRYSGHDDLIRSDVSDISTHTVTYGNIEGNAAKR RKQQYKDSLKKRPASAKSRREFDEIELAYRRRPPRSPDHKRYFRDKEGLRDFYLDQFRTK ENSPHWEHVDLTDIYKERSDDFKRDSVSGGGPCTNRSHIKHGTGDKHGVVSGVPAPWEKN LTNVEWEDRSGGNFCRSCPSKLHNYSTTVTGQNSGRQACIRCEACKKAGNLYDISEDNSL QELDQPAAPVAVTSNASTTKYPQSPTNSKAQKKNRNKLRRQHSYDTFVDLQKEEAALAPR SVSLKDKGRFMDGSPYAHMFEMSAGESTFANNKSSVPTAGHHHHNNPGGGYMLSKSLYPD RVTQNPFIPTFGDDQCLLHGSKSYFFRQPTVAGASKARPDFRALVTNKPVVSALHGAVPA RFQKDICIGNQSNPCVPNNKNPRAFNGSSNGHVYEKLSSIESDV Click to Show/Hide
|
|||||
| 3D Structure | Click to Show 3D Structure of This Target | AlphaFold | ||||
| HIT2.0 ID | T18RS6 | |||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 1 Approved Drugs | + | ||||
| 1 | Alpha 1-PI | Drug Info | Approved | Alpha-1 antitrypsin deficiency | [2], [3] | |
| Clinical Trial Drug(s) | [+] 8 Clinical Trial Drugs | + | ||||
| 1 | CERC-301 | Drug Info | Phase 2 | Major depressive disorder | [4] | |
| 2 | CP-101,606 | Drug Info | Phase 2 | Parkinson disease | [5] | |
| 3 | ELIPRODIL | Drug Info | Phase 2 | Multiple sclerosis | [6] | |
| 4 | MIJ821 | Drug Info | Phase 2 | Major depressive disorder | [7] | |
| 5 | RGH-896 | Drug Info | Phase 2 | Peripheral neuropathy | [8] | |
| 6 | EVT100 | Drug Info | Phase 1 | Major depressive disorder | [9] | |
| 7 | NBQX | Drug Info | Phase 1 | Neurological disorder | [10] | |
| 8 | Neu-2000 | Drug Info | Phase 1 | Cardiac arrest | [11] | |
| Discontinued Drug(s) | [+] 10 Discontinued Drugs | + | ||||
| 1 | EVT-101 | Drug Info | Discontinued in Phase 2 | Neuropathic pain | [12] | |
| 2 | YM-90K | Drug Info | Discontinued in Phase 2 | Convulsion | [13] | |
| 3 | Besonprodil | Drug Info | Discontinued in Phase 1 | Parkinson disease | [14] | |
| 4 | EVT-103 | Drug Info | Discontinued in Phase 1 | Major depressive disorder | [15] | |
| 5 | DIZOCILPINE | Drug Info | Terminated | Cerebrovascular ischaemia | [16], [17] | |
| 6 | L-689560 | Drug Info | Terminated | Neurodegenerative disorder | [18], [19] | |
| 7 | L-698532 | Drug Info | Terminated | Neurological disorder | [20] | |
| 8 | L-698544 | Drug Info | Terminated | Alzheimer disease | [21] | |
| 9 | L-701324 | Drug Info | Terminated | Cerebrovascular ischaemia | [22], [23], [24] | |
| 10 | RO-25-6981 | Drug Info | Terminated | Cancer related pain | [25] | |
| Mode of Action | [+] 6 Modes of Action | + | ||||
| Antagonist | [+] 26 Antagonist drugs | + | ||||
| 1 | Alpha 1-PI | Drug Info | [1] | |||
| 2 | CERC-301 | Drug Info | [26] | |||
| 3 | CP-101,606 | Drug Info | [27] | |||
| 4 | RGH-896 | Drug Info | [8] | |||
| 5 | EVT100 | Drug Info | [9] | |||
| 6 | Neu-2000 | Drug Info | [31] | |||
| 7 | EVT-101 | Drug Info | [32] | |||
| 8 | Besonprodil | Drug Info | [32] | |||
| 9 | EVT-103 | Drug Info | [34] | |||
| 10 | L-689560 | Drug Info | [37] | |||
| 11 | RO-25-6981 | Drug Info | [40] | |||
| 12 | CGP61594 | Drug Info | [37] | |||
| 13 | Conantokins G | Drug Info | [60] | |||
| 14 | Conantokins T | Drug Info | [60] | |||
| 15 | d-AP5 | Drug Info | [37] | |||
| 16 | d-CCPene | Drug Info | [37] | |||
| 17 | LY233053 | Drug Info | [37] | |||
| 18 | NP93-31 | Drug Info | [37] | |||
| 19 | NVP-AAM077 | Drug Info | [67] | |||
| 20 | Ro 63-1908 | Drug Info | [69] | |||
| 21 | Tenocyclidine | Drug Info | [70] | |||
| 22 | UBP141 | Drug Info | [43] | |||
| 23 | [3H]CGP39653 | Drug Info | [37] | |||
| 24 | [3H]CGS19755 | Drug Info | [37] | |||
| 25 | [3H]CPP | Drug Info | [37] | |||
| 26 | [3H]MDL105519 | Drug Info | [37] | |||
| Inhibitor | [+] 88 Inhibitor drugs | + | ||||
| 1 | ELIPRODIL | Drug Info | [28] | |||
| 2 | NBQX | Drug Info | [30] | |||
| 3 | YM-90K | Drug Info | [33] | |||
| 4 | DIZOCILPINE | Drug Info | [35] | |||
| 5 | L-687414 | Drug Info | [36] | |||
| 6 | L-695902 | Drug Info | [36] | |||
| 7 | L-698532 | Drug Info | [38] | |||
| 8 | L-698544 | Drug Info | [36] | |||
| 9 | L-701324 | Drug Info | [38] | |||
| 10 | MDL-105519 | Drug Info | [39] | |||
| 11 | RPR-104632 | Drug Info | [41] | |||
| 12 | (D)-Ala-Pro-Glu | Drug Info | [42] | |||
| 13 | (R)-2-Amino-5-phosphono-pentanoic acid | Drug Info | [43] | |||
| 14 | (R)-2-Amino-7-phosphono-heptanoic acid | Drug Info | [43] | |||
| 15 | 1,3-ditolylguanidine | Drug Info | [44] | |||
| 16 | 2-(4-benzyl-piperidin-1-ylmethyl)-1H-indol-6-ol | Drug Info | [45] | |||
| 17 | 2-(4-Phenoxy-benzyl)-1H-benzoimidazole | Drug Info | [46] | |||
| 18 | 2-(4-Phenoxy-benzyl)-3H-benzoimidazol-4-ol | Drug Info | [46] | |||
| 19 | 2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ol | Drug Info | [46] | |||
| 20 | 2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ylamine | Drug Info | [46] | |||
| 21 | 2-Methylamino-succinic acid(NMDA) | Drug Info | [37], [47] | |||
| 22 | 2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline | Drug Info | [48] | |||
| 23 | 3-Benzoyl-7-chloro-4-hydroxy-1H-quinolin-2-one | Drug Info | [36] | |||
| 24 | 3-Hydroxy-1H-benzo[b]azepine-2,5-dione | Drug Info | [49] | |||
| 25 | 3-Hydroxy-6-methyl-1H-benzo[b]azepine-2,5-dione | Drug Info | [49] | |||
| 26 | 3-Hydroxy-7-nitro-1H-benzo[b]azepine-2,5-dione | Drug Info | [49] | |||
| 27 | 3-Hydroxy-8-methyl-1H-benzo[b]azepine-2,5-dione | Drug Info | [49] | |||
| 28 | 3-phenyl-4-hydroxyquinolin-2(1H)-one | Drug Info | [38] | |||
| 29 | 4,5,7-Trichloro-3-hydroxy-1H-quinolin-2-one | Drug Info | [50] | |||
| 30 | 4,6-Dichloro-1H-indole-2-carboxylic acid | Drug Info | [51] | |||
| 31 | 4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline | Drug Info | [48] | |||
| 32 | 4-Benzyl-1-(2-phenoxy-ethyl)-piperidine | Drug Info | [28] | |||
| 33 | 4-Benzyl-1-phenethyl-piperidine hydrochloride | Drug Info | [52] | |||
| 34 | 4-Bromo-3-hydroxy-1H-quinolin-2-one | Drug Info | [50] | |||
| 35 | 4-Bromo-5,7-dichloro-3-hydroxy-1H-quinolin-2-one | Drug Info | [50] | |||
| 36 | 4-Chloro-3-hydroxy-1H-quinolin-2-one | Drug Info | [50] | |||
| 37 | 4-hydroxy-5-phenylthieno[2,3-b]pyridin-6(7H)-one | Drug Info | [38] | |||
| 38 | 4-[2-(3-Phenyl-propylamino)-ethyl]-phenol | Drug Info | [52] | |||
| 39 | 4-[2-(4-Benzyl-piperidin-1-yl)-ethoxy]-phenol | Drug Info | [28] | |||
| 40 | 4-[2-(4-Phenyl-butoxy)-ethyl]-phenol | Drug Info | [52] | |||
| 41 | 4-[2-(4-Phenyl-butylamino)-ethyl]-phenol | Drug Info | [52] | |||
| 42 | 4-[2-(4-Phenyl-piperidin-1-yl)-ethoxy]-phenol | Drug Info | [28] | |||
| 43 | 4-[2-(5-Phenyl-pentylamino)-ethyl]-phenol | Drug Info | [52] | |||
| 44 | 4-[2-(6-Phenyl-hexylamino)-ethyl]-phenol | Drug Info | [52] | |||
| 45 | 4-[3-(4-Phenyl-butylamino)-propyl]-phenol | Drug Info | [53] | |||
| 46 | 4-[3-(5-Phenyl-pentylamino)-propyl]-phenol | Drug Info | [52] | |||
| 47 | 4-{2-[Ethyl-(4-phenyl-butyl)-amino]-ethyl}-phenol | Drug Info | [52] | |||
| 48 | 5,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione | Drug Info | [54] | |||
| 49 | 5,7-Dichloro-4-hydroxy-3-phenyl-1H-quinolin-2-one | Drug Info | [36] | |||
| 50 | 5,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione | Drug Info | [36] | |||
| 51 | 6,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione | Drug Info | [54] | |||
| 52 | 6-Chloro-1,4-dihydro-quinoxaline-2,3-dione | Drug Info | [55] | |||
| 53 | 6-Methoxy-2-(4-phenoxy-benzyl)-1H-benzoimidazole | Drug Info | [46] | |||
| 54 | 6-Nitro-1,4-dihydro-quinoxaline-2,3-dione | Drug Info | [55] | |||
| 55 | 6-Nitro-2-(4-phenoxy-benzyl)-1H-benzoimidazole | Drug Info | [46] | |||
| 56 | 7-chloro-3-hydroxyquinazoline-2,4-dione | Drug Info | [56] | |||
| 57 | 8-Bromo-3-hydroxy-1H-benzo[b]azepine-2,5-dione | Drug Info | [49] | |||
| 58 | 8-Chloro-3-hydroxy-1H-benzo[b]azepine-2,5-dione | Drug Info | [49] | |||
| 59 | 8-Ethyl-3-hydroxy-1H-benzo[b]azepine-2,5-dione | Drug Info | [49] | |||
| 60 | 8-Fluoro-3-hydroxy-1H-benzo[b]azepine-2,5-dione | Drug Info | [49] | |||
| 61 | Ala-Pro-Glu | Drug Info | [42] | |||
| 62 | AP-7 | Drug Info | [57] | |||
| 63 | Benzyl 4-aminobutyl(3-aminopropyl)carbamate | Drug Info | [58] | |||
| 64 | Conantokin-G | Drug Info | [59] | |||
| 65 | Conantokin-R | Drug Info | [59] | |||
| 66 | DNQX | Drug Info | [61] | |||
| 67 | Gly-Amp-Glu | Drug Info | [42] | |||
| 68 | Gly-b7Pro-Glu | Drug Info | [42] | |||
| 69 | Gly-Hyp-Glu | Drug Info | [42] | |||
| 70 | Gly-Pip-Glu | Drug Info | [42] | |||
| 71 | H-Gly-D-dmP-Glu-OH | Drug Info | [63] | |||
| 72 | H-Gly-dmP-Glu-OH | Drug Info | [63] | |||
| 73 | N,N'-Bis-(4-butoxy-phenyl)-guanidine | Drug Info | [44] | |||
| 74 | N,N'-Bis-(4-butyl-phenyl)-guanidine | Drug Info | [44] | |||
| 75 | N,N'-Bis-(4-ethyl-phenyl)-guanidine | Drug Info | [44] | |||
| 76 | N,N'-Bis-(4-hexyl-phenyl)-guanidine | Drug Info | [44] | |||
| 77 | N,N'-Bis-(4-isopropyl-phenyl)-guanidine | Drug Info | [44] | |||
| 78 | N,N'-Bis-(4-sec-butyl-phenyl)-guanidine | Drug Info | [44] | |||
| 79 | N-(2-methoxybenzyl)cinnamamidine | Drug Info | [64] | |||
| 80 | N-(3-phenethoxybenzyl)-4-hydroxybenzamide | Drug Info | [65] | |||
| 81 | N-(4-(benzyloxy)phenethyl)pyridin-4-amine | Drug Info | [66] | |||
| 82 | Nle-Pro-Glu | Drug Info | [42] | |||
| 83 | Phe-Pro-Glu | Drug Info | [42] | |||
| 84 | PHENCYCLIDINE | Drug Info | [68] | |||
| 85 | Phenethyl-(3-phenyl-propyl)-amine | Drug Info | [52] | |||
| 86 | Phenethyl-(4-phenyl-butyl)-amine | Drug Info | [52] | |||
| 87 | RPR-118723 | Drug Info | [41] | |||
| 88 | TRANSTORINE | Drug Info | [51] | |||
| Modulator | [+] 2 Modulator drugs | + | ||||
| 1 | MIJ821 | Drug Info | [29] | |||
| 2 | CN-2097 | Drug Info | [37] | |||
| Agonist | [+] 5 Agonist drugs | + | ||||
| 1 | (+)-HA966 | Drug Info | [37] | |||
| 2 | (RS)-(tetrazol-5-yl)glycine | Drug Info | [37] | |||
| 3 | D-aspartic acid | Drug Info | [37] | |||
| 4 | homoquinolinic acid | Drug Info | [37] | |||
| 5 | L-aspartic acid | Drug Info | [37] | |||
| Modulator (allosteric modulator) | [+] 1 Modulator (allosteric modulator) drugs | + | ||||
| 1 | DQP-1105 | Drug Info | [62] | |||
| Blocker (channel blocker) | [+] 2 Blocker (channel blocker) drugs | + | ||||
| 1 | N1-dansyl-spermine | Drug Info | [37] | |||
| 2 | [3H]dizocilpine | Drug Info | [37] | |||
| Cell-based Target Expression Variations | Top | |||||
|---|---|---|---|---|---|---|
| Cell-based Target Expression Variations | ||||||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| Ligand Name: Adenosine triphosphate | Ligand Info | |||||
| Structure Description | Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B(S1303D) | PDB:7KL1 | ||||
| Method | X-ray diffraction | Resolution | 2.40 Å | Mutation | Yes | [71] |
| PDB Sequence |
RNKLRRQHDY
1304 DTFVD
|
|||||
|
|
||||||
| Ligand Name: Esketamine | Ligand Info | |||||
| Structure Description | Structure of the human GluN1-GluN2B NMDA receptor in complex with S-ketamine,glycine and glutamate | PDB:7EU8 | ||||
| Method | Electron microscopy | Resolution | 4.07 Å | Mutation | No | [72] |
| PDB Sequence |
SIGIAVILVS
45 DEVAIKDAHE55 KDDFHHLSVV65 PRVELVAMNE75 TDPKSIITRI85 CDLMSDRKIQ 95 GVVFADDTDQ105 EAIAQILDFI115 SAQTLTPILG125 IHGGSSMIMA135 DKDESSMFFQ 145 FGPSIEQQAS155 VMLNIMEEYD165 WYIFSIVTTY175 FPGYQDFVNK185 IRSTIENSFV 195 GWELEDSKIQ217 NQLKKLQSPI227 ILLYCTKEEA237 TYIFEVANSV247 GLTGYGYTWI 257 VPSLVAGDTD267 TVPAEFPTGL277 ISVSYDEWDY287 GLPARVRDGI297 AIITTAASDM 307 LSEHSFIPEP317 KSSCYNTHEK327 QSNMLNRYLI340 NVTFEGRNLS350 FSEDGYQMHP 360 KLVIILLNKE370 RKWERVGKWK380 DKSLQMKYYV390 WPDDHLSIVT410 LEEAPFVIVE 420 SVDPLSGTCM430 RNTVPCQKRI440 VGYIKKCCKG459 FCIDILKKIS469 KSVKFTYDLY 479 LVTNGKHGKK489 INGTWNGMIG499 EVVMKRAYMA509 VGSLTINEER519 SEVVDFSVPF 529 IETGISVMVS539 RSNGTVSPSA549 FLEPFSADVW559 VMMFVMLLIV569 SAVAVFVFEY 579 FTIGKAIWLL609 WGLVFNNSVP619 VQNPKGTTSK629 IMVSVWAFFA639 VIFLASYTAN 649 LAAFMIQEEY659 VDQVSGLSDK669 KFQRPNDFSP679 PFRFGTVPNG689 STERNIRNNY 699 AEMHAYMGKF709 NQRGVDDALL719 SLKTGKLDAF729 IYDAAVLNYM739 AGRDEGCKLV 749 TIGSGKVFAS759 TGYGIAIQKD769 SGWKRQVDLA779 ILQLFGDGEM789 EELEALWLTG 799 ICHNSSQLDI815 DNMAGVFYML825 GAAMALSLIT835 FIC
|
|||||
|
|
||||||
| Click to View More Binding Site Information of This Target with Different Ligands | ||||||
| Different Human System Profiles of Target | Top |
|---|---|
|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Tissue Distribution
of target is determined from a proteomics study that quantified more than 12,000 genes across 32 normal human tissues. Tissue Specificity (TS) score was used to define the enrichment of target across tissues.
The distribution of targets among different tissues or organs need to be taken into consideration when assessing the target druggability, as it is generally accepted that the wider the target distribution, the greater the concern over potential adverse effects
(Nat Rev Drug Discov, 20: 64-81, 2021).
Human Pathway Affiliation
of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function.
Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes
(Pharmacol Rev, 58: 259-279, 2006).
Biological Network Descriptors
of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.
The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information
(Front Pharmacol, 9, 1245, 2018;
Curr Opin Struct Biol. 44:134-142, 2017).
Human Similarity Proteins
Human Tissue Distribution
Human Pathway Affiliation
Biological Network Descriptors
|
|
|
There is no similarity protein (E value < 0.005) for this target
|
|
Note:
If a protein has TS (tissue specficity) scores at least in one tissue >= 2.5, this protein is called tissue-enriched (including tissue-enriched-but-not-specific and tissue-specific). In the plots, the vertical lines are at thresholds 2.5 and 4.
|
| KEGG Pathway | Pathway ID | Affiliated Target | Pathway Map |
|---|---|---|---|
| Ras signaling pathway | hsa04014 | Affiliated Target |
|
| Class: Environmental Information Processing => Signal transduction | Pathway Hierarchy | ||
| Rap1 signaling pathway | hsa04015 | Affiliated Target |
|
| Class: Environmental Information Processing => Signal transduction | Pathway Hierarchy | ||
| cAMP signaling pathway | hsa04024 | Affiliated Target |
|
| Class: Environmental Information Processing => Signal transduction | Pathway Hierarchy | ||
| Neuroactive ligand-receptor interaction | hsa04080 | Affiliated Target |
|
| Class: Environmental Information Processing => Signaling molecules and interaction | Pathway Hierarchy | ||
| Circadian entrainment | hsa04713 | Affiliated Target |
|
| Class: Organismal Systems => Environmental adaptation | Pathway Hierarchy | ||
| Long-term potentiation | hsa04720 | Affiliated Target |
|
| Class: Organismal Systems => Nervous system | Pathway Hierarchy | ||
| Glutamatergic synapse | hsa04724 | Affiliated Target |
|
| Class: Organismal Systems => Nervous system | Pathway Hierarchy | ||
| Dopaminergic synapse | hsa04728 | Affiliated Target |
|
| Class: Organismal Systems => Nervous system | Pathway Hierarchy | ||
| Click to Show/Hide the Information of Affiliated Human Pathways | |||
| Degree | 23 | Degree centrality | 2.47E-03 | Betweenness centrality | 1.72E-03 |
|---|---|---|---|---|---|
| Closeness centrality | 2.40E-01 | Radiality | 1.42E+01 | Clustering coefficient | 1.26E-01 |
| Neighborhood connectivity | 3.07E+01 | Topological coefficient | 6.13E-02 | Eccentricity | 12 |
| Download | Click to Download the Full PPI Network of This Target | ||||
| Chemical Structure based Activity Landscape of Target | Top |
|---|---|
| Drug Property Profile of Target | Top | |
|---|---|---|
| (1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
|
||
| (3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
|
||
| (5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
|
||
| "RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five | ||
| Co-Targets | Top | |||||
|---|---|---|---|---|---|---|
| Co-Targets | ||||||
| Target Poor or Non Binders | Top | |||||
|---|---|---|---|---|---|---|
| Target Poor or Non Binders | ||||||
| Target Regulators | Top | |||||
|---|---|---|---|---|---|---|
| Target-interacting Proteins | ||||||
| Target Profiles in Patients | Top | |||||
|---|---|---|---|---|---|---|
| Target Expression Profile (TEP) | ||||||
| Target-Related Models and Studies | Top | |||||
|---|---|---|---|---|---|---|
| Target Validation | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | NMDA receptor stimulation induces reversible fission of the neuronal endoplasmic reticulum. PLoS One. 2009;4(4):e5250. | |||||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003666) | |||||
| REF 4 | ClinicalTrials.gov (NCT02459236) A Study of Intermittent Doses of CERC-301 in MDD. | |||||
| REF 5 | ClinicalTrials.gov (NCT00073476) A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke. U.S. National Institutes of Health. | |||||
| REF 6 | ClinicalTrials.gov (NCT00001929) Treatment of Parkinson's Disease With Eliprodil. U.S. National Institutes of Health. | |||||
| REF 7 | ClinicalTrials.gov (NCT04722666) Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent. U.S. National Institutes of Health. | |||||
| REF 8 | Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. | |||||
| REF 9 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 10 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4264). | |||||
| REF 11 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025797) | |||||
| REF 12 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023880) | |||||
| REF 13 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002155) | |||||
| REF 14 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013599) | |||||
| REF 15 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030864) | |||||
| REF 16 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2403). | |||||
| REF 17 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000713) | |||||
| REF 18 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4239). | |||||
| REF 19 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001828) | |||||
| REF 20 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006620) | |||||
| REF 21 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003218) | |||||
| REF 22 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4240). | |||||
| REF 23 | Anticonvulsant and behavioral profile of L-701,324, a potent, orally active antagonist at the glycine modulatory site on the N-methyl-D-aspartate receptor complex. J Pharmacol Exp Ther. 1996 Nov;279(2):492-501. | |||||
| REF 24 | L-701,324, a selective antagonist at the glycine site of the NMDA receptor, counteracts haloperidol-induced muscle rigidity in rats. Psychopharmacology (Berl). 1999 Apr;143(3):235-43. | |||||
| REF 25 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009657) | |||||
| REF 26 | Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice. Eur J Pharmacol. 2015 Nov 5;766:1-8. | |||||
| REF 27 | NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol. 2001 Oct 19;429(1-3):71-8. | |||||
| REF 28 | 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000. | |||||
| REF 29 | Clinical pipeline report, company report or official report of Cadent Therapeutics. | |||||
| REF 30 | Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65. | |||||
| REF 31 | Neu2000, an NR2B-selective, moderate NMDA receptor antagonist and potent spin trapping molecule for stroke. Drug News Perspect. 2010 Nov;23(9):549-56. | |||||
| REF 32 | Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. | |||||
| REF 33 | 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7. | |||||
| REF 34 | Clinical pipeline report, company report or official report of Evotec. | |||||
| REF 35 | Synthesis and evaluation of 6,11-ethanohexahydrobenzo[b]quinolizidines: a new class of noncompetitive N-methyl-D-aspartate antagonists. J Med Chem. 1995 Jun 23;38(13):2483-9. | |||||
| REF 36 | Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993). | |||||
| REF 37 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457). | |||||
| REF 38 | Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71. | |||||
| REF 39 | CoMFA, synthesis, and pharmacological evaluation of (E)-3-(2-carboxy-2-arylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acids: 3-[2-(3-aminophenyl)-2... J Med Chem. 2005 Feb 24;48(4):995-1018. | |||||
| REF 40 | Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71. | |||||
| REF 41 | Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81. | |||||
| REF 42 | New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. | |||||
| REF 43 | Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem. 2005 Apr 7;48(7):2627-37. | |||||
| REF 44 | Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302. | |||||
| REF 45 | Selective NR1/2B N-methyl-D-aspartate receptor antagonists among indole-2-carboxamides and benzimidazole-2-carboxamides. J Med Chem. 2007 Mar 8;50(5):901-14. | |||||
| REF 46 | NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96. | |||||
| REF 47 | 2,4-Dihydro-3H-1,2,4-triazol-3-ones as anticonvulsant agents. J Med Chem. 1990 Oct;33(10):2772-7. | |||||
| REF 48 | 4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor an... Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62. | |||||
| REF 49 | Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. | |||||
| REF 50 | 3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996). | |||||
| REF 51 | 3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspart... J Med Chem. 1990 Nov;33(11):2944-6. | |||||
| REF 52 | Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. | |||||
| REF 53 | Structure-activity relationship for a series of 2-substituted 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indoles: potent subtype-selective inhibitors of N-... Bioorg Med Chem Lett. 1999 Jun 7;9(11):1619-24. | |||||
| REF 54 | 3-hydroxy-quinazoline-2,4-dione as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2345-9. | |||||
| REF 55 | 5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and... J Med Chem. 1997 Oct 24;40(22):3679-86. | |||||
| REF 56 | Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Syn... J Med Chem. 2006 Oct 5;49(20):6015-26. | |||||
| REF 57 | Bioisosteric replacement of the alpha-amino carboxylic acid functionality in 2-amino-5-phosphonopentanoic acid yields unique 3,4-diamino-3-cyclobut... J Med Chem. 1992 Dec 11;35(25):4720-6. | |||||
| REF 58 | Polyamines and the NMDA receptor: modifying intrinsic activities with aromatic substituents. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2837-41. | |||||
| REF 59 | Novel conantokins from Conus parius venom are specific antagonists of N-methyl-D-aspartate receptors. J Biol Chem. 2007 Dec 21;282(51):36905-13. | |||||
| REF 60 | Powerful antinociceptive effects of the cone snail venom-derived subtype-selective NMDA receptor antagonists conantokins G and T. Pain. 2003 Jan;101(1-2):109-16. | |||||
| REF 61 | Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antago... J Med Chem. 1991 Apr;34(4):1243-52. | |||||
| REF 62 | Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators. Mol Pharmacol. 2011 Nov;80(5):782-95. | |||||
| REF 63 | The neuroprotective activity of GPE tripeptide analogues does not correlate with glutamate receptor binding affinity. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3396-400. | |||||
| REF 64 | Indole-2-carboxamidines as novel NR2B selective NMDA receptor antagonists. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5439-41. | |||||
| REF 65 | Structure-activity relationship study of novel NR2B-selective antagonists with arylamides to avoid reactive metabolites formation. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5537-42. | |||||
| REF 66 | Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetr... J Med Chem. 2007 Feb 22;50(4):807-19. | |||||
| REF 67 | Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach. J Neurosci. 2006 Feb 1;26(5):1331-3. | |||||
| REF 68 | Synthesis and biological activity of conformationally restricted analogs of milnacipran: (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopro... J Med Chem. 1996 Nov 22;39(24):4844-52. | |||||
| REF 69 | Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist. J Pharmacol Exp Ther. 2002 Sep;302(3):940-8. | |||||
| REF 70 | The binding of [3H]thienyl cyclohexylpiperidine ([3H]TCP) to the NMDA-phencyclidine receptor complex. Neuropharmacology. 1989 Jan;28(1):1-7. | |||||
| REF 71 | CaMKII binds both substrates and activators at the active site. Cell Rep. 2022 Jul 12;40(2):111064. | |||||
| REF 72 | Structural basis of ketamine action on human NMDA receptors. Nature. 2021 Aug;596(7871):301-305. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.